Chronic Pelvic Floor Myalgia (Investigational Adjunct)

Investigational adjunct for chronic pelvic floor myalgia; pelvic-floor physical therapy is first-line; biofeedback, trigger-point injection, and (for selected refractory cases) onabotulinumtoxinA remain evidence-based.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?: Not FDA-cleared for chronic pelvic floor myalgia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational; intra-cavitary placement (rectum, vagina, urethra) is absolutely contraindicated.
¿Qué evidencia existe?: Tier C (investigational). No controlled trials exist for hirudotherapy in pelvic floor myalgia. Evidence-based first-line management is specialized pelvic-floor physical therapy (internal and external myofascial release, biofeedback, relaxation training), with adjunctive trigger-point injection, and onabotulinumtoxinA for refractory cases. Multidisciplinary care across urology, gynecology, gastroenterology, pain medicine, and mental health is often needed.
Riesgos principales: Bleeding from bite sites for 6 to 24 hours after detachment
Bruising and tenderness in the perineal or ischial region for 5 to 14 days
Local skin infection or Aeromonas infection in a region adjacent to anus and genitals
Allergic reaction to leech saliva
Triggering or worsening of myofascial spasm if a bite site is too close to a trigger point
Delay of evidence-based pelvic-floor physical therapy, biofeedback, or onabotulinumtoxinA
Catastrophic risk if a practitioner attempts intra-rectal, intra-vaginal, or peri-urethral placement (absolute contraindication)
Quién no debería considerar esto: Anyone offered intra-rectal, intra-vaginal, or urethral placement (this is absolutely contraindicated)
Anyone with active pelvic infection (PID, prostatitis, abscess)
Patients with inflammatory bowel disease and perianal involvement
Patients within 12 weeks of pelvic or anorectal surgery
Patients with anal fissure, fistula, or bleeding hemorrhoid
Pregnant or lactating patients
Patients who have not completed at least 12 weeks of specialized pelvic-floor PT
Qué preguntar a su clínico: Have I had a specialized pelvic-floor physical therapy program for at least 12 weeks?
Has trigger-point injection or onabotulinumtoxinA been considered for refractory disease?
Have my bowel, bladder, and sexual dysfunction symptoms been addressed in a multidisciplinary plan?
Where exactly will the leech be placed — confirm it is external skin only?
What is the practitioner's experience with this indication and Aeromonas-prevention plan?
What is the realistic expected benefit given the absence of controlled trials?
Cuándo buscar atención urgente: Severe pelvic, rectal, or genital pain that is new or sharply increased
Fever above 38.0 C / 100.4 F or chills
Visible bleeding from the rectum, vagina, or urethra
Spreading redness, warmth, pus, or red streaks at any bite site
Bleeding from a bite site lasting more than 24 hours
Difficulty urinating or defecating, or new urinary retention

Qué NO significa esto

It does not replace specialized pelvic-floor physical therapy, which has the strongest evidence.
It does not address concurrent bowel, bladder, or sexual dysfunction that often accompany pelvic floor myalgia.
Leeches are never placed inside the rectum, vagina, or urethra.
Only anecdotal evidence exists.

Referencias cruzadas de seguridad

Clinical Profile

Category: urogenital
ICD-10: N94.89, M62.838, K59.4
Safety tier: high

Evidence Summary

Chronic pelvic floor myalgia (hypertonic pelvic floor dysfunction, levator ani syndrome, coccygodynia variants) is myofascial dysfunction of the pelvic floor producing pelvic, perineal, or rectal pain, often with bowel, bladder, or sexual symptoms. Evidence-based first-line management is specialized pelvic-floor physical therapy (internal and external myofascial release, biofeedback, relaxation training), with adjunctive trigger-point injection, and onabotulinumtoxinA for refractory cases. Multidisciplinary care (urology, gynecology, gastroenterology, pain medicine, mental health) is often needed. No published controlled trials of hirudotherapy exist for pelvic floor myalgia. The perineum and ischiorectal region are uniquely high-risk for bleeding and infection; intra-rectal or vaginal application is absolutely contraindicated.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Intra-rectal, intra-vaginal, or urethral placement (absolute)
Active pelvic infection (PID, prostatitis, abscess)
Inflammatory bowel disease with perianal involvement
Recent pelvic or anorectal surgery
Anal fissure, fistula, or hemorrhoid with bleeding
Pregnancy or lactation

Related Conditions

Peyronie's Disease (Stable Phase)

Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.

Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)

Investigational use for category III CP/CPPS; small case series suggest symptom reduction. Multimodal therapy remains standard.

Chronic Prostatitis / Chronic Pelvic Pain Syndrome (Extended Protocol)

Investigational extended-protocol adjunct for NIH Category III chronic prostatitis/CPPS; small case series only; UPOINT-directed therapy remains primary.

Interstitial Cystitis / Bladder Pain Syndrome (Investigational)

Highly investigational adjunct for IC/BPS refractory to conventional therapy; case reports only; AUA-guideline stepwise therapy remains primary.